Dual treatment with CCR2 and CXCR2 inhibitors can significantly increase the suppression of tumor-infiltrating myeloid cells in PDAC compared with either strategy alone and enhance the chemotherapeutic efficacy of FOLFIRINOX (5-Fluorouracil, irinotecan, and oxaliplatin) [107]. The gene discussed is CCR2; the disease is neoplasm.